Cardiovascular Mortality in Type 2 Diabetes Patients with Incident Exposure to Insulin Glargine. (14th June 2015)

• Record Type: Journal Article
• Authors: Ioacara, Sorin; Guja, Cristian; Reghina, Aura; Martin, Sorina; Sirbu, Anca; Fica, Simona
• Other Names: Strain David Academic Editor.
• Is Part Of: Journal of diabetes research. Volume 2015(2015)
• Publication Date: 2015-06-14
• Subjects: Diabetes -- Periodicals; Diabetes -- Pathophysiology -- Periodicals; Diabetes -- Prevention -- Periodicals; Diabetes -- Etiology -- Periodicals; Diabetes -- Epidemiology -- Periodicals; Diabetes -- Pathogenesis -- Periodicals; 616.462005
• DOI: 10.1155/2015/962346
• Languages: English
• ISSNs: 2314-6745

Abstract

Abstract : The study investigated the impact of insulin glargine exposure on cardiovascular mortality in type 2 diabetes patients with incident insulin initiation. All consecutive diabetes patients aged >40 years were screened at their first diabetes outpatient visit between 01/01/2001 and 12/31/2008 (n = 79869 ). Exclusion criteria restricted the cohort to 4990 incident insulin users, aged 40–79 years, who were followed up for death until 12/31/2011. Baseline was defined 6 months after insulin initiation. Adjusted time-dependent competing risk regression analysis was performed. Mean baseline age was62 ± 9 years, with mean follow-up of4.7 ± 1.9 years. During 23179 person-years of exposure time, there were 887 deaths (521 cardiovascular). Glargine cumulative time exposure significantly lowered overall cardiovascular, subhazard ratio (SHR) 0.963 (CI 95% 0.944–0.981, p < 0.001 ), and myocardial infarction mortality, SHR 0.945 (CI 95% 0.899–0.994, p = 0.028 ), but not stroke mortality. Glargine cumulative dose exposure (10, 000 IU increments) significantly lowered cardiovascular mortality, SHR 0.977 (CI 95% 0.960–0.993, p = 0.006 ), but not for myocardial infarction and stroke. Both cumulative dose and time exposure to insulin glargine were associated with lower cardiovascular mortality. The effect was mostly driven by myocardial infarction end point, supporting the concept of macrovascular benefit for basal analogue insulin use in type 2 diabetes.